Improved characteristics and protective efficacy in an animal model of E. coli -derived recombinant double-layered rotavirus virus-like particles

Highlights • Self-assembly of recombinant rotavirus virus-like particles. • Post-purification assembly yields homogeneous particle. • Virion-like epitopes on virus-like particles by on antibody binding analysis. • Improved stability, antigenicity and protective efficacy of double-layered VP2/6 VLPs....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-04, Vol.32 (17), p.1921-1931
Hauptverfasser:	Li, Tingdong, Lin, Haijun, Zhang, Yue, Li, Min, Wang, Daning, Che, Yaojian, Zhu, Yinbin, Li, Shaowei, Zhang, Jun, Ge, Shengxiang, Zhao, Qinjian, Xia, Ningshao
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Animals Antibodies, Monoclonal, Murine-Derived - immunology Antibodies, Viral - blood Antigens, Viral - immunology Applied microbiology Biological and medical sciences Capsid Proteins - immunology Diarrhea score Double-layered particle Escherichia coli Female Fundamental and applied biological sciences. Psychology Maternal antibody Mice Mice, Inbred BALB C Microbiology Miscellaneous Post purification assembly Recombinant Proteins - immunology Rotavirus Rotavirus Infections - prevention & control Rotavirus Vaccines - immunology Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Virus-Like Particle - immunology Virology Virus-like particles
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Self-assembly of recombinant rotavirus virus-like particles. • Post-purification assembly yields homogeneous particle. • Virion-like epitopes on virus-like particles by on antibody binding analysis. • Improved stability, antigenicity and protective efficacy of double-layered VP2/6 VLPs. • Resemblance of Escherichia coli -derived VLPs to virus-derived double-layered particles.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.01.093